A new clinical trial has shown that a daily pill, known as daraxonrasib, could potentially double the survival time for patients suffering from pancreatic cancer.
Conducted on May 31, 2026, the trial highlights the urgent need for innovative treatments in the fight against this deadly disease.
These findings may offer hope to many who are affected by pancreatic cancer, a condition known for its low survival rates.